Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)

Condition(s) studied

Investigational drug(s) / intervention(s)

Chemotherapy: Any chemotherapy regimen that is used in the adjuvant setting

Study summary

The goal of this observational study is to compare chemotherapy types that are given after surgery for biliary tract cancers. The main question it aims to answer is:

Are any of the chemotherapy regimens more effective in preventing recurrence, providing longer survival, or having less toxicity?

Nationwide multicenter retrospective data will be collected.

Eligibility

Primary outcome measure(s)

• Recurrence-free survival — From the date of adjuvant chemotherapy initiation until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 180 months
  The length of time from the start of adjuvant chemotherapy to the date of the first loco-regional or systemic recurrence or death
• Overall survival — From the date of adjuvant chemotherapy initiation until the date of death from any cause, assessed up to 180 months
  The length of time from the start of adjuvant chemotherapy to the date of death

Trial sites (1)

More Ankara University trials in Turkey

Other trials for the same condition